Table 2.
Pharmacological interventions by disease severity.
| III n = 259 (69.4%) |
IV n = 114 (30.6%) |
p | C n = 48 (12.9%) |
D n = 325 (87.1%) |
p | |
|---|---|---|---|---|---|---|
| Only bronchodilators (LAMA and/or LABA) | 29 (11.2%) | 3 (2.6%) | 0.007 | 9 (18.8%) | 23 (7.1%) | 0.007 |
| Inhaled corticosteroids (ICS) with or without bronchodilators | 225 (86.9%) | 110 (96.5%) | 0.005 | 39 (81.3%) | 296 (91.1%) | 0.036 |
| Triple inhaled therapy (LAMA, LABA and ICS) | 196 (75.7%) | 85 (74.6%) | 0.818 | 31 (64.6%) | 250 (76.9%) | 0.064 |
| Influenza vaccination | 198 (76.4%) | 84 (73.7%) | 0.567 | 30 (62.5%) | 252 (77.5%) | 0.024 |
| Pneumococcal vaccination | 156 (60.2%) | 79 (69.3%) | 0.095 | 24 (50%) | 211 (64.9%) | 0.046 |
Pharmacological treatment groups and vaccinations distributed over disease severity according to GOLD 2011 stage III/IV and GOLD 2014 group C/D. LAMA = long-acting muscarinic antagonists, LABA = long-acting beta-2-agonists, ICS = inhaled corticosteroids.